alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 10.1






Exhibit 10.1


DESCRIPTION OF COMPENSATION ARRANGEMENTS 
FOR NON-EMPLOYEE DIRECTORS 
For the period between each annual meeting of shareholders, non-employee directors receive the following compensation: 
		
	•
	annual retainer - $75,000, payable at the director’s election in shares of State Street common stock or in cash; 


		
	•
	meeting fees - $1,500 for each Board and committee meeting attended, together with reimbursement of expenses incurred as a result of attending such meetings, payable in cash; 


		
	•
	an annual common stock award in an amount of shares equal to $140,000 divided by the closing price of the stock on the date of the annual meeting that begins the period (with additional stock amounts to reflect dividends if the award is deferred); 


		
	•
	a pro-rated annual retainer and annual common stock award for any director joining the Board after the  annual meeting that begins the period; 


		
	•
	an additional annual retainer for the Lead Director of $90,000, payable at the director’s election in shares of State Street common stock or in cash; 


		
	•
	an additional annual retainer for the Examining and Audit Committee Chair and for the Risk and Capital Committee Chair of $25,000, payable at the director’s election in shares of State Street common stock or in cash; 


		
	•
	an additional annual retainer for the Chair of the Executive Compensation Committee of $20,000, payable at the director’s election in shares of State Street common stock or in cash;


		
	•
	an additional annual retainer for the Chair of the Nominating and Corporate Governance Committee of $15,000, payable at the director’s election in shares of State Street common stock or in cash; and 


		
	•
	an additional annual retainer for each member of the Examining and Audit Committee and for each member of the Risk and Capital Committee, other than the Chairs, of $10,000, payable at the director’s election in shares of State Street common stock or in cash. 


Pursuant to State Street’s Deferred Compensation Plan for Directors, directors may elect to defer the receipt of 0% or 100% of their (1) retainers, (2) meeting fees, or (3) annual award of shares of common stock. Directors also may elect to receive all of their retainers in cash or shares of common stock. Directors who elect to defer the cash payment of their retainers or meeting fees may also make notional investment elections with respect to those deferrals, with a choice of notional investment fund returns. To the extent the amounts are deferred they will (a) be paid as elected by the director, on either the date of the director’s termination of service on the Board or on the earlier of such termination and a future date specified, and (b) be paid in the form elected by the director as either a lump sum or in installments over a two- to five-year period.
United States 

Office of 

Personnel Management 

The Federal Government’s Human Resources Agency

Retirement and Insurance Service 

Benefits Administration Letter 

Number: 00-221 Date: November 17, 2000 

Subject: Federal Employees' Group Life Insurance: Additional Information on the 

Transition to a New Presidential Administration

Purpose 

The purpose of this Benefits Administration Letter (BAL) is to give you additional information 

for employees separating for the transition to a new presidential administration. 

Background 

The Office of Personnel Management's web site contains a guide for agencies to use for both new 

and separating employees as part of the transition to a new presidential administration 

(www.opm.gov/transition). This transition guide omitted information on portability of Option B 

coverage under FEGLI for separating employees. 

Additional Information 

As explained in BAL 99-210 and in the FEGLI Handbook, employees whose life insurance is 

terminating due to separation (or completion of 12 months in nonpay status) may port their 

Option B coverage if they meet the 5-year/all-opportunity requirement. Please make this 

information available to eligible employees who are separating as part of the transition and to 

anyone doing transition counseling. 

 Abby L. Block, Chief 

 Insurance Policy 

 and Information Division 

Civil Service Federal Employees Federal Employees Federal Employees 

Retirement Group Life Health Benefits Retirement 

System Insurance Program System
LG-2014.06.30- EX10.4 AmendmentNo1toSitherwoodSeveranceBenefitsAgreement




AMENDMENT NO. 1 TO SEVERANCE BENEFITS AGREEMENT


THIS AMENDMENT NO. 1 TO SEVERANCE BENEFITS AGREEMENT (the “Amendment”) is entered into as of the 1st of August, 2014, between The Laclede Group, Inc., a Missouri corporation (“Laclede” or the “Company”), and Suzanne Sitherwood (“Executive”).


WHEREAS, the above-named parties in 2011 entered into that certain Severance Benefits Agreement to assure the Company that it will have the continued dedication of Executive, including the availability of her advice and counsel notwithstanding the possibility, threat, or occurrence of a Change in Control of the Company, and to induce Executive to remain in the employ of the Company; and


WHEREAS, the parties desire to amend the Severance Benefits Agreement to continue the Term to January 1, 2015 in accordance with the terms and conditions set forth hereinbelow.


NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Company and Executive agree as follows:


1.Section 1(a) of the Severance Benefits Agreements is hereby amended by deleting “August 31, 2014” and replacing it with “December 31, 2014.”


2.All capitalized terms not specifically defined in this Amendment shall have the same meaning assigned to them in the Severance Benefits Agreement.


3.    Except as expressly amended herein, the Severance Benefits Agreement shall remain in full force and effect according to the terms and conditions thereof.


4.    This Amendment may be executed in any number of counterparts, which together will constitute a fully executed agreement.


IN WITNESS WHEREOF, the parties have executed this Amendment as of the day and year first above written.


THE LACLEDE GROUP, INC.


	
						
	By: /s/ Edward L. Glotzbach
	 
	 
	 /s/ Suzanne Sitherwood
	 

	Name:  Edward L. Glotzbach
	 
	 
	Suzanne Sitherwood
	 

	Title:    Chair, Compensation Committee
	 
	 

	 
	 
	 
	 
	 

	ATTEST:
	 
	 
	 
	 

	 /s/ Mary C. Kullman
	 
	 
	 
	 

	Corporate Secretary
Exhibit 32.1





CERTIFICATION PURSUANT TO


18 U.S.C. § 1350


AS ADOPTED PURSUANT TO


SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Report of Point.360 (the “Company”) on Form 10-Q for the period ended March 31, 2011, as filed with the Securities and Exchange Commission (the “Report”), I, Haig S. Bagerdjian, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:





(1)
The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of  1934; and





(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.




/s/ Haig S. BagerdjianHaig S. BagerdjianChief Executive OfficerMay 13, 2011
Electronically Filed

Intermediate Court of Appeals

CAAP-18-0000190

30-APR-2019

08:18 AM
##### 



Exhibit 32.1
 
    /s/ Gary L. Whitlock

Gary L. WhitlockPresident and Manager (Principal Executive Officer)May 11, 2007
Exhibit 10.7

 

CONFIDENTIAL TREATMENT REQUESTED

 

AMENDMENT AGREEMENT

 

TO THE

 

RESEARCH COLLABORATION AND LICENSE AGREEMENT

 

This AMENDMENT AGREEMENT TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT (“Amendment Agreement”), effective as of October 8, 2007, is entered into by and between Vitae Pharmaceuticals, Inc (“Vitae”), with offices at 502 West Office Center Drive, Ft. Washington, PA 19034, USA. (taxpayer ID number 04-3567753), and Boehringer Ingelheim International GmbH (“BI”), with offices at **** (VAT ID number ****).  Vitae and BI may each be referred to as a “Party” or together as the “Parties.”

 

This Amendment Agreement to the Research Collaboration and License Agreement dated October 2, 2007 between the Parties is to clarify that Vitae has the right to use the Patents assigned pursuant to Section 14.4.1 (a) (iii) under the terms and conditions of the Research Collaboration and License Agreement, namely in line with its Section 14.4.1(a)(i), and in order to achieve this objective, to amend the last sentence of Section 14.4.1(a)(iii).

 

Article I —

 

The last sentence of Section 14.4.1(a)(iii) shall be replaced as follows:

 

“Notwithstanding any statement to the contrary contained in this Agreement, all Vitae assignments effected pursuant to this Section 14.4.1(a)(iii) will be deemed to have occurred during the Term.”

 

Article II -

 

In all other regards, the provisions of the Research Collaboration and License Agreement shall apply.

 

IN WITNESS WHEREOF, Vitae and BI, by their duly authorized officers, have executed this Agreement as of the Effective Date.

 

	
VITAE   PHARMACEUTICALS, INC.
    	
BOEHRINGER INGELHEIM
    
	
 
    	
INTERNATIONAL GMBH
    
	
 
    	
 
    
	
By:   ****
    	
By:   ****
    
	
 
    	
 
    
	
Name:   ****
    	
Name:   ****
    
	
 
    	
 
    
	
Title:   ****
    	
Title:   ****
    


 

****CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 

1
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 04-6041

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

versus

EDGAR NELSON PITTS,

Defendant - Appellant.

Appeal from the United States District Court for the Western

District of Virginia, at Roanoke. James C. Turk, Senior District

Judge. (CR-94-68; CA-00-848-7)

Submitted: July 29, 2004 Decided: August 3, 2004

Before LUTTIG, MICHAEL, and DUNCAN, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Edgar Nelson Pitts, Appellant Pro Se. Thomas Jack Bondurant, Jr.,

Assistant United States Attorney, Roanoke, Virginia, for Appellee.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
- 2 -

PER CURIAM:

Edgar Pitts seeks to appeal the district court’s order

denying a post-judgment motion in his 28 U.S.C. § 2255 (2000)

proceeding. Pitts cannot appeal this order unless a circuit judge

or justice issues a certificate of appealability, and a certificate

of appealability will not issue absent a “substantial showing of

the denial of a constitutional right.” 28 U.S.C. § 2253(c)(2)

(2000). A habeas appellant meets this standard by demonstrating

that reasonable jurists would find that his constitutional claims

are debatable and that any dispositive procedural rulings by the

district court are also debatable or wrong. See Miller-El v.

Cockrell, 537 U.S. 322, 336 (2003); Slack v. McDaniel, 529 U.S.

473, 484 (2000); Rose v. Lee, 252 F.3d 676, 683 (4th Cir. 2001).

We have independently reviewed the record and conclude Pitts has

not made the requisite showing. Accordingly, we deny a certificate

of appealability and dismiss the appeal. We dispense with oral

argument because the facts and legal contentions are adequately

presented in the materials before the court and argument would not

aid the decisional process.

DISMISSED
# EUR-Lex - 32011M6181 - EN

Important legal notice

*|*

# 32011M6181

**Commission Decision of 27/06/2011 declaring a concentration to be compatible with the common market (Case No COMP/M.6181 - SEB TRYGG LIV HOLDING / IRISH LIFE INTERNATIONAL) according to Council Regulation (EC) No 139/2004 (Only the English text is authentic) **

*

*

|EUROPEAN COMMISSION |

Brussels , 27.6.2011

C(2011) 4703 final PUBLIC VERSION

SIMPLIFIED MERGER PROCEDURE

To the notifying party | |

Dear Madam(s) and/or Sir(s),

Subject: Case No COMP/M.6181 - SEB TRYGG LIV HOLDING/ IRISH LIFE INTERNATIONAL Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004 [1]

1. On 20/05/2011, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by the undertaking SEB Trygg Liv Holding AB ("SEB Trygg Liv", Sweden), controlled by Skandinaviska Enskilda Banken AB ("SEB Group", Sweden) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Irish Life International Limited ("ILI", Ireland) by way of purchase of shares.

2. The business activities of the undertakings concerned are:

- for SEB Trygg Liv : life insurance products in Estonia, Latvia, Lithuania and Sweden;

- for SEB Group : North European financial group active in retail banking, merchant banking, wealth management, and life insurance.

- ILI : life assurance company, active in the transaction of single premium unit linked life assurance and investment business in the international market [2] .

3. After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraph 5(c)i and 5(c)ii of the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 [3] .

4. For the reasons set out in the Notice on a simplified procedure, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation.

For the Commission (signed) Alexander ITALIANER Director General

[1]OJ L 24, 29.1.2004, p. 1 ("the Merger Regulation"). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ("TFEU") has introduced certain changes, such as the replacement of "Community" by "Union" and "common market" by "internal market". The terminology of the TFEU will be used throughout this decision.

[2] Publication in the Official Journal of the European Union No C 161, 31.05.2011, p.4.

[3] OJ C 56, 5.3.2005, p. 32.
**Exhibit 32.2**

** **

**Certification of Chief Financial Officer pursuant to**

**18 U.S.C. Section 1350,**

**as adopted pursuant to**

**Section 906 of the Sarbanes-Oxley Act of 2002**

 

In connection with theQuarterly Report on Form 10-Q of Pzena Investment Management, Inc.(the “Company”) for the quarter ending March 31, 2008, as filed with theSecurities and Exchange Commission on the date hereof (the “Report”), Wayne A.Palladino, as Chief Financial Officer of the Company certifies, pursuant to18 U.S.C. § 1350, as adopted pursuant to § 906 of theSarbanes-Oxley Act of 2002, that:

 

(1) TheReport fully complies with the requirements of section 13(a) or 15(d) ofthe Securities Exchange Act of 1934; and

 

(2) Theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.

 
| /s/  Wayne A.  Palladino |                    |
|------------------------------------|-------------------------|
| Name:                              | Wayne A. Palladino      |
| Title:                             | Chief Financial Officer |
|                                    |                         |  |

 

Dated: May 14, 2008

 

----
## Harding BASE-13x10 Design 1% SO2SO3-B&V-GH030731-1

PROJECT IPALCO Harding St Unit 7 DATE PREPARED BY G. Holscher REVISION 0 PROPOSAL NO. GH030731-1

Case

Load Fuel lb/h °F Vol% Vol%,w Vol%,d lb/MMBtu SO 2 ppmvd,act.O2 SO 3 ppmvd,act.O2 Particulate lb/hr % absolute % absolute °C absolute

Orientation m3 [-] [-] m3 [-] m2/m3
mm mm n x n 6 x 12

n x n 13 x 10

mm x mm 957 x 1911 ft x ft 3.14 x 6.27
mm ft

mm x mm 12781 x 19930 ft x ft 41.93 x 65.39 kg lb 2673 Module frame material H II 4.50 Reactor dimensions: length x width
Weight per module incl. catalyst 1212 Module dimensions: length x width
height 1372 Catalyst elements per one module Number of layers per reactor 2 Module arrangement per layer Pitch of catalyst 6.7 Catalyst length 1032 Cells of catalyst n x n 22 Specific area of catalyst Ap 510 Number of units 1 Catalyst Volume, total 434.6 Catalyst Volume 434.6 Number of SCR reactors 1 Temperature distribution 10 

### Catalyst Design: vertical 34647.0 Molar ratio distribution 10 Velocity distribution 15 Inlet NOx 0.39 1033.9 15.5 O 2 -actual 3.30 O 2 -reference 3.00 Gas temperature 763 H 2 O 10.34 Full Load 

### Design Basis: Coal Gas flow 4613433 7/31/2003

Limiting case 13x10 Design 1% SO2 to SO3

Print Date - 8/4/2003 Page 1 of 2

## Harding BASE-13x10 Design 1% SO2SO3-B&V-GH030731-1

PROJECT IPALCO Harding St Unit 7 DATE PREPARED BY G. Holscher REVISION 0 FILE GH030731-1

Case

Load Fuel NOx outlet ppmvd, ref.O 2 NOx reduction % ppmvd,ref.O2 NH3 consumption kg/h per reactor lb/h NH3 consumption kg/h total lb/h
Catalyst pressure drop, dirty mbar inwg mm WC % hr / years 16000 / 2 Catalyst life 4.6 1.9 44.9 SO 2/SO 3conversion rate 1.0 284.5 627.2 284.5 627.2

37.8 87.18 NH 3slip 2.0 Limiting case 13x10 Design 1% SO2 to SO3 Full Load 

### Catalyst Performance: Coal 7/31/2003

Print Date - 8/4/2003 Page 2 of 2
# EUR-Lex - 32011M6115 - EN

Important legal notice

*|*

# 32011M6115

**Commission Decision of 07/03/2011 declaring a concentration to be compatible with the common market (Case No COMP/M.6115 - STEINHOFF / CONFORAMA) according to Council Regulation (EC) No 139/2004 (Only the English text is authentic) **

*

*

|EUROPEAN COMMISSION |

Brussels , 7.3.2011

SG-Greffe(2011) D/3564

C(2011) 1621 final

PUBLIC VERSION

SIMPLIFIED PROCEDURE MERGER PROCEDURE ARTICLE 6(1)(b) DECISION

To the notifying party: |

Dear Madam(s) and/or Sir(s),

Subject: Case No COMP/M.6115 – STEINHOFF/ CONFORAMA Notification of 03.02.2011 pursuant to Article 4 of Council Regulation (EC) No 139/2004 [1] Publication in the Official Journal of the European Union No C 45, 12.02.2011, p.20

1. On 3 February 2011, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by which Steinhoff International Holdings Limited (‘Steinhoff’, South Africa) acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control over the Conforama Group (‘Conforama’, France), by way of purchase of shares.

2. The business activities of the undertakings concerned are:

- for Steinhoff: manufacturing, wholesale and retailing of furniture and household goods, provision of logistics and warehousing services;

- for Conforama: retailing of furniture, domestic equipment, decoration products, electronic appliances and consumer electronics.

3. After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraph 5(c) of the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 [2] .

4. For the reasons set out in the Notice on a simplified procedure, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation.

For the Commission

(signed)

Alexander ITALIANER Director General

[1]OJ L 24, 29.1.2004, p. 1 ("the Merger Regulation"). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ("TFEU") has introduced certain changes, such as the replacement of "Community" by "Union" and "common market" by "internal market". The terminology of the TFEU will be used throughout this decision.

[2] OJ C 56, 5.3.2005, p. 32.
Exhibit
        32.1
 
 Certification
        of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted
        pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  CERTIFICATION
        OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
        PURSUANT TO SECTION 906 OF TEHE SARBANES-OXLEY ACT OF 2002
 
 I,
        Charles Camorata, certify, pursuant to 18 U.S.C. Section 1350, as adopted
        pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly
        Report of Skreem Entertainment Corporation on Form 10-QSB for the quarterly
        period ended June 30, 2007 fully complies with the requirements of Section 13(a)
        or
        15(d) of the Securities Exchange Act of 1934 and that information contained
        in
        such Form 10-QSB fairly presents in all material respects the financial
        condition and results of operations of Skreem Entertainment
        Corporation
  By:
                  /s/ Charles CamorataName:
                  Charles CamorataTitle:
                  Chief Executive OfficerSeptember
                  10, 2007
[Federal Register Volume 89, Number 191 (Wednesday, October 2, 2024)]
[Notices]
[Page 80272]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-22693]


-----------------------------------------------------------------------

POSTAL SERVICE


Product Change--Priority Mail and USPS Ground Advantage[supreg] 
Negotiated Service Agreement

AGENCY: Postal Service<SUP>TM</SUP>.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Postal Service gives notice of filing a request with the 
Postal Regulatory Commission to add a domestic shipping services 
contract to the list of Negotiated Service Agreements in the Mail 
Classification Schedule's Competitive Products List.

DATES: Date of required notice: October 2, 2024.

FOR FURTHER INFORMATION CONTACT: Sean Robinson, 202-268-8405.

SUPPLEMENTARY INFORMATION: The United States Postal Service[supreg] 
hereby gives notice that, pursuant to 39 U.S.C. 3642 and 3632(b)(3), on 
September 26, 2024, it filed with the Postal Regulatory Commission a 
USPS Request to Add Priority Mail & USPS Ground Advantage[supreg] 
Contract 366 to Competitive Product List. Documents are available at 
www.prc.gov, Docket Nos. MC2024-763, K2024-56.

Sean Robinson,
Attorney, Corporate and Postal Business Law.
[FR Doc. 2024-22693 Filed 10-1-24; 8:45 am]
BILLING CODE 7710-12-P
Belews Creek Physchem Effluent: Questionable Mercury Results

Results having "< -->" in the column to the left indicates the parameter was not detected above the laboratory detection limit

Lab File Name Sample Date BDL Mercury (ppb)

Prism 08‐JUN‐0318 06/16/08 0.0110

Prism 08‐JUN‐0425 06/23/08 0.0059Prism 08‐JUN‐0552 06/30/08 0.1500Prism 08‐JUL‐0125 07/07/08 0.0590Prism 08‐JUL‐0312 07/14/08 0.3500Prism 08‐AUG‐0098 08/04/08 0.0049Prism 08‐AUG‐0234 08/11/08 0.0048Prism 08‐AUG‐0396 08/18/08 0.024Prism 08‐AUG‐0483 08/25/08 0.027Prism 08‐AUG‐0640 09/02/08 0.0031Prism 08‐SEP‐0137 09/08/08 0.0027Prism 08‐SEP‐0308 09/15/08 0.012Prism 08‐SEP‐0324 09/22/08 0.0081Prism 08‐SEP‐0418 09/29/08 0.0034Prism 08‐DEC‐0103 12/03/08 0.019Prism 08‐DEC‐0201rev 12/10/08 0.015Prism 08‐DEC‐0313 12/17/08 0.0076Prism 08‐DEC‐0347 12/22/08 0.02Prism 08‐DEC‐0348 12/29/08 0.012